TICKERNERD
Menu
CELCCELCHealthcare · Biotechnology

CELC Stock Forecast: Celcuity, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$65
−0.43% on the day

The 13 Wall Street analysts covering Celcuity, Inc. hold a median 12-month price target of $155 — +137.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 24 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.2B
Ticker Nerd rank
28/ 100
Median analyst target
$155
Analysts covering
13
Revenue$0.0
Operating income−$66.1M
Net income−$78.9M
Free cash flow−$55.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+15.4%
1M
−18.4%
YTD
−34.5%
1Y
−7.5%
From 52W high
−55.0%
From 52W low
+15.4%
$57
$145
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CELC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Celcuity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Oct 2026
28/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
87
Momentum
65
Quality
56
Volatility
51
Accruals
38
Growth
31
Revisions
29
Size
29
Issuance
6

Value (87): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CELC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CELC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160$180Jan 26Apr 26Jul 26Oct 26CELCHigh $177Median $155Low $130

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
13 Buy0 Hold0 Sell
Low $130Median $155High $177

The green dot is the last close — the median target sits +137.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
22 Oct 2026Cantor FitzgeraldInitiatesOverweight$140
21 Oct 2026TD CowenReiteratesBuy$145
30 Sept 2026NeedhamMaintainsBuy$140 → $134
30 Sept 2026NeedhamMaintainsBuy—
17 Sept 2026JP MorganInitiatesOverweight$157
17 Sept 2026JP MorganInitiatesOverweight—
17 Aug 2026CitizensReiteratesMarket Outperform—
17 Aug 2026CitizensReiteratesMarket Outperform$177
17 Aug 2026GuggenheimMaintainsBuy—
17 Aug 2026GuggenheimMaintainsBuy$165 → $175
14 Aug 2026HC Wainwright & Co.ReiteratesBuy$155
14 Aug 2026HC Wainwright & Co.ReiteratesBuy—
14 Aug 2026NeedhamMaintainsBuy$157 → $140
14 Aug 2026NeedhamMaintainsBuy—
14 Aug 2026StifelMaintainsBuy$175 → $150
14 Aug 2026StifelMaintainsBuy—
15 July 2026CitizensMaintainsMarket Outperform$160 → $177
15 July 2026CitizensMaintainsMarket Outperform—
15 July 2026HC Wainwright & Co.MaintainsBuy$145 → $155
15 July 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CELC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

CELC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, Celcuity, Inc. returned −7.5% against +14.3% for the S&P 500, dividends included.

CELC vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26CELCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CELC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Celcuity, Inc. (CELC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−17.2×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
−280.0×

Cheaper than 99% of US stocks

EV / EBITDA
−15.3×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1433.7%

Higher than 1% of US stocks

Return on assets
−25.8%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Celcuity, Inc. (CELC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Celcuity, Inc. has a market value of $3.2B and an enterprise value of $3.2B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$226.5M.

  • Diluted earnings per share, trailing twelve months: $−4.30.

  • Free cash flow in the twelve months to 30 June 2026: −$192.3M, after $271K of capital spending.

  • Shares outstanding: 48.9M.

  • Trailing P/E: −17.2×; forward P/E: −815.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Celcuity, Inc. employs 155 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Oct 2026

Data provided by Twelve Data

Peers

CELC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CELCCelcuity, Inc.$3.2B28
IDYAIDEAYA Biosciences, Inc.$3.2B85
VKTXViking Therapeutics, Inc.$3.1B35
TARSTarsus Pharmaceuticals, Inc.$3.4B84
XENEXenon Pharmaceuticals, Inc.$3.4B38
ACADACADIA Pharmaceuticals, Inc.$3.4B74
ELVNEnliven Therapeutics, Inc.$3.0B61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Celcuity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CELC news & analysis

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

GlobeNewsWire · 24 Oct 2026positive

Celcuity presented updated results from the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 study at ESMO Congress 2026. Among patients without liver metastases, median progression-free survival was 21.5 months with the gedatolisib triplet and 11.5 months with the doublet, versus 9.1 months with alpelisib plus fulvestrant.

Why it matters — The results provide CELC watchers with updated comparative progression-free survival data for gedatolisib in this patient subgroup.

Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026

GlobeNewsWire · 23 Oct 2026positive

Celcuity presented updated Phase 1b/2 study data on gedatolisib plus darolutamide in men with metastatic castration-resistant prostate cancer at the ESMO Congress 2026. Among patients who had received prior abiraterone, median radiographic progression-free survival was 15.7 months, and the six-month rate was 82.2%.

Why it matters — The update provides CELC watchers with reported efficacy measures for the combination in a defined patient group.

New Strong Sell Stocks for October 14th

Zacks Investment Research · 14 Oct 2026negative

Zacks Investment Research added Celcuity (CELC) to its Zacks Rank #5 (Strong Sell) List on October 14, 2026, alongside ADDYY and CNL.

Why it matters — CELC watchers may note the stock’s inclusion in Zacks’ Strong Sell list.

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

GlobeNewsWire · 5 Oct 2026positive

Celcuity announced that a late-breaking rapid oral presentation and three poster presentations featuring data from its clinical trials of gedatolisib will be presented at the ESMO Congress 2026 in Madrid, Spain, October 23-27. The presentations cover subgroup analyses from the VIKTORIA-1 trial in HR+/HER2- advanced breast cancer and from a Phase 1b trial of gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.

Why it matters — Presentations at a major oncology congress could increase visibility for Celcuity's gedatolisib clinical data among researchers and the broader oncology community.

Celcuity Appoints David Gryska To Its Board Of Directors

GlobeNewsWire · 2 Oct 2026positive

Celcuity, Inc. announced the appointment of David Gryska to its Board of Directors. Mr. Gryska brings decades of strategic and financial leadership experience to the board.

Why it matters — A CELC watcher would care because adding an experienced financial and strategic leader to the board could strengthen the company's governance and oversight.

FAQ

Frequently asked questions about CELC stock

What is the CELC stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Celcuity, Inc. have a median 12-month price target of $155, with estimates ranging from $130 to $177. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CELC stock a buy right now?

Of the 13 analysts covering Celcuity, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Celcuity, Inc. 28 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CELC?

As at 24 Oct 2026, Celcuity, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (87 of 100).

Will CELC stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +137.4% from the last close, and Ticker Nerd's factor model ranks Celcuity, Inc. 28 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CELC stock forecast for 2030?

No analyst covering Celcuity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $130 to $177 over the next 12 months.

How has CELC stock performed over the past year?

Celcuity, Inc. returned -7.5% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Celcuity, Inc. do?

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications.

What is the latest news on CELC?

The most recent item we track (GlobeNewsWire, 24 Oct 2026): "Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026". Celcuity presented updated results from the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 study at ESMO Congress 2026. Among patients without liver metastases, median progression-free survival was 21.5 months with the gedatolisib triplet and 11.5 months with the doublet, versus 9.1 months with alpelisib plus fulvestrant.

Company

About Celcuity, Inc.

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s current work centers on cancer treatments that act on the PAM pathway, including its lead therapeutic candidate gedatolisib, which is being developed for advanced breast cancer and metastatic castration-resistant prostate cancer. Celcuity also operates a cellular analysis platform used to identify abnormal signaling activity in tumors and help guide the development of precision oncology therapies. Its business is concentrated in oncology drug development, with programs aimed at patients whose cancers are driven by specific molecular pathways. Headquartered in Minneapolis, Minnesota, Celcuity is positioned as a research-driven biotech company working across therapeutic development and biomarker-based cancer analysis.

CEO Mr. Brian F. Sullivan · 155 employees · United States · https://www.celcuity.com